Individuals with melanoma were treated with penile sparing surgery; two are alive without disease, the first is alive with disease, and one individual with metastasis at demonstration died of disease at 16

Individuals with melanoma were treated with penile sparing surgery; two are alive without disease, the first is alive with disease, and one individual with metastasis at demonstration died of disease at 16.3 months. without disease, the first is alive with disease, and one patient with metastasis at demonstration died of disease at Rabbit Polyclonal to TEAD1 16.3 months. The individuals with sarcoma and deep-seated or node-positive disease died of disease at a mean of 49.7 months. Two individuals with NSC16168 EPD were treated with wide local excision of the lesions and were both pT1Nx. The remaining individual experienced sebaceous carcinoma treated with excisional biopsy and was free of disease at 32.0 months. == Conclusions == Non-SCC of the penis is definitely primarily treated surgically, with the goal of total excision at the time of treatment. The utilization of lymphadenectomy is definitely less obvious in these malignancies, but aggressive approaches should be considered in appropriate individuals. Tumor stage and nodal status are important in determining patient results. Keywords:Penile malignancy, Melanoma, Sarcoma == Intro == Penile malignancy is definitely a rare malignancy that may affect approximately 1,500 males in the NSC16168 USA in 2012 and will account for over 300 deaths [1]. Greater than 95 % of penile cancers are squamous cell carcinoma (SCC), while non-SCC penile cancers are exceedingly rare. Several case reports and small series are published for non-SCC malignancies; however, due to small numbers, there is no consensus concerning the optimal management of these rare cancers. Melanomas and sarcomas have been the most commonly reported penile malignancies, with series published from our center, as well as others [24]. Herein, we describe our single-center, 15-yr experience with main noninvasive and invasive non-SCC of the penis, including treatment and results for four individuals with melanoma, five individuals with sarcoma, two individuals with extramammary Pagets disease (EPD), and one patient with sebaceous carcinoma. == Methods == After obtaining Institutional Review Table approval, we examined the Memorial Sloan-Kettering Malignancy Center database to identify individuals treated for main penile malignancy from January 1996 to August 2011. We recognized 141 individuals, 12 of whom experienced non-SCC of the penis. Demographic and medical data were collected for each patient, and pathological data were reviewed. For individuals with melanoma, TNM staging was performed according NSC16168 to the 2010 AJCC/UICC staging criteria [5]. Individuals with sarcoma were staged according to the AJCC 7th release for soft cells sarcomas [6]. Individuals with EPD and sebaceous carcinoma were classified according to the AJCC 7th release NSC16168 TNM system for penile carcinoma [6]. All individuals experienced a history and physical exam, with attention to the inguinal region and pores and skin, and chest X-ray. CT and/or MRI was performed in the discretion of the treating physician, most commonly in individuals with higher-stage disease. Individuals were surgically treated by means of either a WLE, with the corpora cavernosa acting as the deep medical margin and a margin of pores and skin determined to be negative by freezing section, or partial penectomy, which included resection of the corpora cavernosa and the urethra. Lymphadenectomy was performed in the discretion of the treating physician; this is due to the lack of recommendations for these rare subtypes of penile malignancy. Lymphadenectomy was approached using a sentinel lymph node sampling in one patient, while the remainder of the individuals experienced either ipsilateral or contralateral superficial and/or inguinal node dissection. Adjuvant or salvage chemotherapy and radio-therapy were given according to the discretion of the treating physician. Follow-up was determined from the time of analysis to most recent check out or day of death, and time to recurrence was determined from the time of medical resection to the day of recurrence. == Results == Table 1summarizes the medical data for individuals treated for main.